
Phio Pharmaceuticals (NASDAQ: PHIO) Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762
Pathologic Complete Response reported for 2 patients with cutaneous Squamous Cell Carcinoma Marlborough, Massachusetts– January 13, 2025) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA […]